Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Change in Accured Expenses (2016 - 2025)

Integra Lifesciences Holdings' Change in Accured Expenses history spans 17 years, with the latest figure at $23.0 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 529.48% year-over-year to $23.0 million; the TTM value through Dec 2025 reached $26.7 million, up 1099.4%, while the annual FY2025 figure was $26.7 million, 1099.4% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $23.0 million at Integra Lifesciences Holdings, up from $5.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $23.0 million in Q4 2025 and bottomed at -$19.2 million in Q1 2024.
  • The 5-year median for Change in Accured Expenses is $3.8 million (2023), against an average of $2.7 million.
  • The largest annual shift saw Change in Accured Expenses skyrocketed 1944.11% in 2022 before it tumbled 380.33% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$984000.0 in 2021, then surged by 1944.11% to $18.1 million in 2022, then crashed by 89.46% to $1.9 million in 2023, then plummeted by 380.33% to -$5.4 million in 2024, then soared by 529.48% to $23.0 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Change in Accured Expenses are $23.0 million (Q4 2025), $5.8 million (Q3 2025), and $15.9 million (Q2 2025).